



Financial Tear Sheet

Corporate Profile

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and progressing its pipeline of novel therapeutic candidates in cancer, cachexia (wasting syndrome) and Pulmonary Arterial Hypertension (PAH).

AVEO Oncology
Investor Relations
Phone: 617-588-1960
E-mail:
ir@aveooncology.com

Stock Performance

AVEO (COMMON STOCK)

Exchange	NASDAQ (US Dollar)
Price	\$3.11
Change (%)	▲ 0.05 (1.63%)
Volume	1,832,698
52 Week Low	\$0.50
Market Cap	\$367,979,433
Rolling EPS	-0.74
PE Ratio	N/A
Shares Outstanding	118,321,361

Data as of 11/17/17 4:00 p.m. ET



Recent Headlines

11/15/17
EUSA Pharma and AVEO Oncology Announce the First Commercial Launch of FOTIVDA® (tivozanib)

11/08/17
AVEO Oncology to Present at Upcoming Conferences

11/07/17
AVEO Reports Third Quarter 2017 Financial Results and Provides Business Update

Events

DATE	TITLE
11/28/17 10:00 a.m. ET	AVEO Oncology at the Piper Jaffray 29th Annual Healthcare Conference Location Lotte New York Palace Hotel

SEC Filings

FILING DATE FORM

11/07/17	8-K
11/07/17	10-Q
11/03/17	8-K
08/21/17	4

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed